Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.41 |
| ▸ | PDE4A | P27815 | 10/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586152 | 0.90 | PDE4A (0.42) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL6582645 | 0.85 | HMGCR (0.46) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL6585029 | 0.83 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL6587471 | 0.81 | POLB (0.48) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL7429364 | 0.80 | KMT2A (0.41) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7424191 | 0.79 | KMT2A (0.41) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7539115 | 0.78 | LMNA (0.42) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7287220 | 0.77 | KDM4E (0.50) | PDE4BLMNAKDM4E | |
| SCHEMBL6586929 | 0.75 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6583922 | 0.68 | PDE4D (0.44) | PDE4BPDE4APDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| EP-1042300-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032456-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | PDE4B 9/4885PDE4A 7/4885PDE4C 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.